Paradigm Biocapital Sells $44.5 Million Stake in Erasca Following Significant Share Price Increase
On May 15, 2026, Paradigm Biocapital Advisors disclosed the sale of a significant portion of its stake in Erasca (ERAS), valued at approximately $44.5 million during Q1 2026. The move follows a massive 716.5% surge in Erasca's share price over the past year, outperforming major indices like the S&P 500.
Tickers: $ERAS